Catalyst Pharmaceuticals and Teva Reach Settlement Over Firdapse Patent Dispute

In a recent legal development, Florida-based Catalyst Pharmaceuticals Inc. has successfully resolved its patent infringement litigation with Teva Pharmaceuticals in a New Jersey federal court. The dispute centered around Catalyst’s flagship drug, Firdapse, which treats a rare autoimmune disorder. Under the terms of the settlement, Catalyst has granted Teva the rights to market a generic version of the drug beginning in 2035, as reported by Law360. This agreement marks a significant step in the ongoing negotiations between the two pharmaceutical companies, potentially impacting the market for treatments of rare diseases.